tiprankstipranks
Global Medical REIT Inc (GMRE)
:GMRE

Global Medical REIT (GMRE) AI Stock Analysis

Compare
761 Followers

Top Page

GM

Global Medical REIT

(NYSE:GMRE)

64Neutral
Global Medical REIT's strong revenue growth and operational efficiency are significant strengths, supported by a robust balance sheet. The stock's technical indicators show bullish momentum, but the valuation appears stretched with a high P/E ratio. The earnings call revealed both strategic successes and some operational challenges. Overall, the stock presents a mixed profile with solid fundamentals but potential overvaluation concerns.
Positive Factors
Acquisitions
GMRE announced a $70mm portfolio acquisition without increasing leverage to inappropriate levels, demonstrating strong acquisition strategies.
New Ventures
The company formed a new venture with Heitman, focusing on a core-plus investment strategy, allowing expansion of its acquisition pipeline without additional balance sheet risk.
Tenant Management
The announcement of a replacement tenant for a hospital formerly leased by Steward Healthcare removes an overhang and is a positive development.
Negative Factors
Capital Markets Challenges
Analyst remains at a Market Perform rating as capital markets present challenges for the company.
Expense Increase
Expenses rose by 15% from the previous year due to the cost associated with the CEO succession plan.
Stock Trading and Financing
Management may need to use the credit facility for a newly announced portfolio deal given the stock has traded down and limited its ability to finance with equity.

Global Medical REIT (GMRE) vs. S&P 500 (SPY)

Global Medical REIT Business Overview & Revenue Model

Company DescriptionGlobal Medical REIT Inc. is net-lease medical office REIT that acquires purpose-built specialized healthcare facilities and leases those facilities to strong healthcare systems and physician groups with leading market share.
How the Company Makes MoneyGlobal Medical REIT generates revenue primarily through rental income from its portfolio of healthcare properties. The company leases its facilities to various healthcare operators, such as hospitals and clinics, under long-term, triple-net lease agreements. These leases ensure that tenants cover most operating expenses, including property taxes, insurance, and maintenance costs, providing GMRE with a stable and predictable cash flow. Additionally, GMRE may enhance revenue through strategic acquisitions of high-quality medical properties, which can increase its asset base and rental income. The company's financial performance is also supported by its ability to maintain strong relationships with healthcare providers and its expertise in identifying lucrative investment opportunities within the healthcare real estate market.

Global Medical REIT Financial Statement Overview

Summary
Global Medical REIT demonstrates strong revenue growth and operational efficiency, evidenced by high gross and EBIT margins. The balance sheet shows a robust equity base and no debt, enhancing financial stability. Cash flow metrics highlight strong cash generation. However, low net profit and return on equity suggest areas for improvement in profitability.
Income Statement
72
Positive
Global Medical REIT has shown a consistent increase in total revenue over the years, indicating growth in its operations. The Gross Profit Margin is strong at 99.88%, reflecting efficient cost management. However, the Net Profit Margin is low at 0.58%, suggesting high operating and non-operating expenses. The EBIT and EBITDA margins are robust at 78.94%, showing operational efficiency.
Balance Sheet
60
Neutral
The company has a solid equity base, with an Equity Ratio of 42.52%, indicating a strong reliance on equity financing. The absence of debt in the latest year is a positive sign, reducing financial risk. However, Return on Equity is low at 0.15%, indicating limited returns to shareholders.
Cash Flow
68
Positive
The Operating Cash Flow to Net Income Ratio is high at 86.36, showing strong cash generation relative to net income. Free Cash Flow has grown significantly, indicating improved liquidity and the ability to reinvest in the business. The Free Cash Flow to Net Income Ratio is also favorable at 86.36.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
138.78M140.93M137.28M115.94M93.73M
Gross Profit
138.63M54.72M112.09M100.45M82.86M
EBIT
109.53M37.94M38.83M37.12M16.55M
EBITDA
91.47M111.67M96.49M84.00M53.00M
Net Income Common Stockholders
6.63M20.61M-5.23M-2.07M-20.61M
Balance SheetCash, Cash Equivalents and Short-Term Investments
6.82M26.40M4.02M7.21M5.51M
Total Assets
1.26B1.27B1.39B1.26B1.10B
Total Debt
653.59M618.91M694.12M571.73M586.58M
Net Debt
646.78M616.80M690.10M564.52M581.07M
Total Liabilities
700.57M661.89M744.20M625.91M643.15M
Stockholders Equity
534.13M583.58M632.98M622.78M444.81M
Cash FlowFree Cash Flow
70.05M58.39M-79.66M-132.69M-184.27M
Operating Cash Flow
70.05M68.44M76.54M68.97M34.52M
Investing Cash Flow
-45.94M67.62M-137.25M-194.66M-223.67M
Financing Cash Flow
-21.89M-143.79M62.41M127.70M192.72M

Global Medical REIT Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price8.38
Price Trends
50DMA
8.12
Positive
100DMA
8.11
Positive
200DMA
8.43
Negative
Market Momentum
MACD
0.08
Positive
RSI
49.81
Neutral
STOCH
12.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMRE, the sentiment is Neutral. The current price of 8.38 is below the 20-day moving average (MA) of 8.54, above the 50-day MA of 8.12, and below the 200-day MA of 8.43, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 49.81 is Neutral, neither overbought nor oversold. The STOCH value of 12.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GMRE.

Global Medical REIT Risk Analysis

Global Medical REIT disclosed 66 risk factors in its most recent earnings report. Global Medical REIT reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Global Medical REIT Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
NHNHI
77
Outperform
$3.37B23.9010.53%4.82%4.88%0.41%
DODOC
72
Outperform
$14.37B57.033.29%5.89%23.82%-37.59%
64
Neutral
$605.13M686.181.19%9.95%-0.43%-94.73%
VTVTR
63
Neutral
$29.99B343.000.80%2.64%9.48%
61
Neutral
$4.74B18.45-3.52%10.74%5.97%-21.87%
HRHR
60
Neutral
$5.81B-10.95%7.34%-5.62%-140.10%
MPMPW
56
Neutral
$3.71B-38.69%7.53%14.19%-331.18%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GMRE
Global Medical REIT
8.38
0.56
7.16%
DOC
Healthpeak Properties
20.16
2.90
16.80%
NHI
National Health Investors
73.81
14.25
23.93%
VTR
Ventas
67.63
25.46
60.37%
MPW
Medical Properties
6.17
1.93
45.52%
HR
Healthcare Realty Trust
16.57
3.62
27.95%

Global Medical REIT Earnings Call Summary

Earnings Call Date: Feb 27, 2025 | % Change Since: 1.21% | Next Earnings Date: Apr 30, 2025
Earnings Call Sentiment Neutral
The call highlighted strong portfolio performance with significant acquisitions and successful joint venture formation, but also noted challenges such as a reduction in FFO due to severance costs, a major tenant bankruptcy, and increased expenses. Despite the positive achievements, these challenges cannot be overlooked.
Highlights
Strong Portfolio Performance
Portfolio occupancy was 96.4% with a weighted average lease term of 5.6 years and a rent coverage ratio of 4.5 times.
Significant Acquisition Activity
Completed the acquisition of a 15-property portfolio for $80.3 million and entered into another purchase agreement for five properties for $69.6 million at a 9% cap rate.
Successful Dispositions
Generated $40.5 million in gross proceeds from the sale of four medical facilities, resulting in a gain of $5.8 million.
Heitman Joint Venture
Formed a joint venture with Heitman, contributing two properties and maintaining a 12.5% ownership stake.
Revenue Growth
Total revenues for Q4 2024 increased by 6.7% compared to the prior year, reaching $35.2 million.
Lowlights
Reduction in FFO
FFO attributable to common stockholders and non-controlling interest decreased from $13.3 million to $11.1 million in Q4 2024, primarily due to $3.2 million in severance-related costs.
Prospect Medical Group Bankruptcy
Prospect Medical Group filed for Chapter 11, impacting approximately $2.4 million in outstanding lease payments.
Increase in G&A Expenses
G&A expenses increased to $7.7 million in Q4 2024 from $4.2 million in the prior year, mainly due to the CEO succession plan costs.
Impairment Loss
Recognized a $1.7 million impairment loss related to the Derby, Kansas facility.
Company Guidance
During Global Medical REIT's fourth quarter 2024 earnings call, the company provided several key financial metrics and strategic updates. The portfolio maintained a high occupancy rate of 96.4% with a weighted average lease term of 5.6 years and a rent coverage ratio of 4.5 times. The net income attributable to common shareholders for the quarter was $1.4 million, or $0.02 per share, a turnaround from a net loss in the same quarter of the previous year. Funds from operations (FFO) and adjusted funds from operations (AFFO) per share were $0.15 and $0.22, respectively, reflecting impacts from $3.2 million in severance-related costs. The company completed acquisitions totaling $80.3 million at an 8% cap rate and $69.6 million at a 9% cap rate. Dispositions generated $40.5 million in gross proceeds with a gain of $5.8 million. The balance sheet showed gross real estate investments of $1.5 billion and total gross debt of $651 million, with 79% being fixed-rate. The 2025 AFFO per share is projected to be between $0.89 and $0.93, excluding one-time CEO succession expenses. The guidance assumes no further acquisition or disposition activity beyond what has already been announced.

Global Medical REIT Corporate Events

Executive/Board Changes
Global Medical REIT Announces Leadership Transition Plan
Neutral
Jan 8, 2025

Global Medical REIT announced the transition of Jeffrey Busch from his role as CEO while maintaining his position as non-executive Chairman of the Board. The company is conducting a search for a new CEO to lead the company forward, with Lori Wittman appointed as lead independent director to help guide this transition, ensuring continued value for stakeholders.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.